- Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
- Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
- Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
- Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
- Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
- Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
- Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
More ▼
Key statistics
On Friday, Jazz Pharmaceuticals PLC (JAZZ:NSQ) closed at 110.01, 6.80% above its 52-week low of 103.01, set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 110.14 |
---|---|
High | 111.55 |
Low | 108.58 |
Bid | 105.99 |
Offer | 115.00 |
Previous close | 109.29 |
Average volume | 614.93k |
---|---|
Shares outstanding | 63.04m |
Free float | 61.28m |
P/E (TTM) | 22.70 |
Market cap | 6.93bn USD |
EPS (TTM) | 4.85 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼